SCHEMBL6032178

SCHEMBL6032178

COC(=O)C1CCN(C2CCCCC2)CC1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.62
POLB P06746 2/20 0.57
TP53 P04637 1/20 0.56
ALDH1A1 P00352 3/20 0.53
OPRM1 P35372 1/20 0.52
OPRD1 P41143 1/20 0.52
OPRK1 P41145 1/20 0.52
OGFRL1 Q5TC84 1/20 0.52
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
CHRM2 P08172 3/20 0.46
CHRM4 P08173 3/20 0.46
CHRM1 P11229 3/20 0.46
CHRM3 P20309 3/20 0.46
GAA P10253 1/20 0.45
HSD17B10 Q99714 1/20 0.45
SIGMAR1 Q99720 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19616801 0.91 SMN1; SMN2 (0.56) SMN1; SMN2POLBTP53ALDH1A1OPRM1
SCHEMBL21851141 0.90 TP53 (0.56) SMN1; SMN2POLBTP53ALDH1A1OPRM1
SCHEMBL16695511 0.89 SMN1; SMN2 (0.53) SMN1; SMN2POLBTP53ALDH1A1OPRM1
SCHEMBL5068809 0.85 SMN1; SMN2 (0.53) SMN1; SMN2POLBTP53ALDH1A1OPRM1
SCHEMBL5068807 0.85 SMN1; SMN2 (0.53) SMN1; SMN2POLBTP53ALDH1A1OPRM1
SCHEMBL3274422 0.83 SMN1; SMN2 (0.50) SMN1; SMN2POLBTP53ALDH1A1OPRM1
SCHEMBL2942040 0.83 SMN1; SMN2 (0.50) SMN1; SMN2POLBTP53ALDH1A1OPRM1
SCHEMBL2942042 0.83 SMN1; SMN2 (0.50) SMN1; SMN2POLBTP53ALDH1A1OPRM1
SCHEMBL16217913 0.82 CHRM1 (0.52) SMN1; SMN2POLBTP53ALDH1A1OPRM1
SCHEMBL16210548 0.82 SMN1; SMN2 (0.51) SMN1; SMN2POLBTP53ALDH1A1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060241123-A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2006-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241123-A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators MC4R, MC5R, MC3R SMN1; SMN2 1508/4885POLB 2972/4885TP53 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.